VAR2 Pharma’s co-authors have published research in the medical journal Cancers that describes the expression of oncofetal chondroitin sulfate in non-small cell lung cancer. The study shows that oncofetal chondroitin sulfate is a prognostic biomarker and an actionable glycosaminoglycan target in non-small cell lung cancer. Read more:
